Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SMUP-IA-01 is an intra-articular injectable therapy composed of allogeneic umbilical cord blood-derived mesenchymal stem cells, developed using the SMUP (Small cell + Ultra Potent + Scale UP) cell platform by Medipost. It is designed for the treatment and prevention of osteoarthritis, particularly knee osteoarthritis. The drug leverages mesenchymal stem cells' ability to modulate inflammation, reduce pain, and promote tissue regeneration in affected joints. SMUP-IA-01 can be mass-produced via bioreactor technology and is formulated for frozen storage to facilitate distribution and commercialization. Clinical trials have demonstrated its safety profile and potential efficacy in improving joint function and reducing pain after a single intra-articular injection[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SMUP-IA-01.